Form 4: Rapport Therapeutics' Chief Scientific Officer Acquires Stock Options

David Bredt, Chief Scientific Officer of Rapport Therapeutics, acquired stock options for 28,302 shares of common stock on June 6, 2024, at an exercise price of $17.

Summary

• On June 6, 2024, David Bredt, the Chief Scientific Officer of Rapport Therapeutics, acquired stock options representing the right to buy 28,302 shares of the company's common stock.
• The exercise price for these options is $17 per share.
• The options vest over a period of four years, with 25% vesting on June 6, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• Following this transaction, Bredt directly owns 28,302 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The granting of stock options is generally seen as a positive incentive for management.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects part of the incentive structure used to retain and motivate key personnel like the Chief Scientific Officer.

Stakeholder Impact

• The granting of stock options aligns the interests of the Chief Scientific Officer with those of the shareholders, incentivizing him to increase the company's value.

Key Dates